Sign in to view content

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch

Estephania Feria, MD

Video
Published 2019

Related

Prevalence and Risk Factors for Early Hydroxychloroquine Retinopathy
Bobeck S Modjtahedi, MD
On Demand Cases, Courses, and Papers
2017
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2024
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more